FindTrial
Sign In

A Study to Understand Why Some Blood Cancer Patients Do Not Respond Well to Platelet Transfusions.

Incidence and Predictors of Platelet Transfusion Refractoriness in Hemato-Oncology Patients Receiving Prophylactic Single Donor Platelet Support: A Prospective Observational Study - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2026/07/114189
Enrollment
180
Registered
2026-07-16
Start date
Unknown
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: C00-D49- Neoplasms

Interventions

Intervention1: Nil: Nil

Sponsors

Dr Akshay Batra
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Age equal to or more than 18 years. 2. Diagnosed case of hematological malignancy. 3. No bleeding, or, bleeding less than WHO Grade 2. 4. Receiving prophylactic Single Donor Platelet transfusions. 5. At least two sequential platelet transfusion episodes during the study period. 6. Availability of pre-transfusion platelet counts within 12 hours. 7. Willingness to provide written informed consent.

Exclusion criteria

Exclusion criteria: 1. Patients with DIC. 2. Patients with Acute Promyelocytic Leukemia. 3. Patients who have received concurrent platelet transfusion within previous 24 hours. 4. Patients with severe transfusion reactions leading to inability to evaluate post-transfusion platelet response. 5. Patients who are stem cell transplant recipients.

Design outcomes

Primary

MeasureTime frame
Incidence of Platelet Transfusion Refractoriness among hemato-oncology patients receiving prophylactic SDP support.Timepoint: 1 to 4 Hours Post-Transfusion, and, 18 to 24 Hours Post-Transfusion.—

Secondary

MeasureTime frame
Identification of predictors associated with PTR.Timepoint: 1 to 4 Hours Post-Transfusion, and, 18 to 24 Hours Post-Transfusion.;Association between immune and non-immune factors with low post-transfusion platelet increment.Timepoint: 1 to 4 Hours Post-Transfusion, and, 18 to 24 Hours Post-Transfusion.;Frequency of non-immune-mediated PTR.Timepoint: On achieving final sample size, or 18 months, whichever is earlier.;Frequency of immune-mediated PTR.Timepoint: On achieving final sample size, or 18 months, whichever is earlier.;Mean platelet increment and corrected count increment following SDP transfusion.Timepoint: 1 to 4 Hours Post-Transfusion, and, 18 to 24 Hours Post-Transfusion.;Association of ABO compatibility and platelet storage duration with platelet response.Timepoint: 1 to 4 Hours Post-Transfusion, and, 18 to 24 Hours Post-Transfusion.—

Countries

India

Contacts

Public ContactDr Akshay Batra

Homi Bhabha Cancer Hospital, Tata Memorial Centre, Varanasi

ritusharma4694@gmail.com9679594694

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Aug 10, 2026